- Home
- GBLI vs CTNM Comparison
GBLI vs CTNM Comparison
Compare GBLI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- CTNM
- Stock Information
- Founded
- GBLI 2016
- CTNM 2009
- Country
- GBLI United States
- CTNM United States
- Employees
- GBLI N/A
- CTNM N/A
- Industry
- GBLI Property-Casualty Insurers
- CTNM
- Sector
- GBLI Finance
- CTNM
- Exchange
- GBLI Nasdaq
- CTNM Nasdaq
- Market Cap
- GBLI 496.2M
- CTNM 377.6M
- IPO Year
- GBLI 2003
- CTNM 2024
- Fundamental
- Price
- GBLI $33.62
- CTNM $12.77
- Analyst Decision
- GBLI
- CTNM Strong Buy
- Analyst Count
- GBLI 0
- CTNM 4
- Target Price
- GBLI N/A
- CTNM $29.25
- AVG Volume (30 Days)
- GBLI 4.8K
- CTNM 148.5K
- Earning Date
- GBLI 11-07-2024
- CTNM 02-16-2025
- Dividend Yield
- GBLI 4.16%
- CTNM N/A
- EPS Growth
- GBLI 90.04
- CTNM N/A
- EPS
- GBLI 2.92
- CTNM N/A
- Revenue
- GBLI $442,500,000.00
- CTNM N/A
- Revenue This Year
- GBLI N/A
- CTNM N/A
- Revenue Next Year
- GBLI $8.39
- CTNM N/A
- P/E Ratio
- GBLI $11.65
- CTNM N/A
- Revenue Growth
- GBLI N/A
- CTNM N/A
- 52 Week Low
- GBLI $27.47
- CTNM $12.33
- 52 Week High
- GBLI $37.00
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- GBLI 30.49
- CTNM N/A
- Support Level
- GBLI $35.69
- CTNM N/A
- Resistance Level
- GBLI $36.51
- CTNM N/A
- Average True Range (ATR)
- GBLI 0.78
- CTNM 0.00
- MACD
- GBLI -0.30
- CTNM 0.00
- Stochastic Oscillator
- GBLI 13.51
- CTNM 0.00
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.